Table 3.
Treatment | 90Y SIRT | MMC Cohort A 1x6mg |
MMC Cohort B 1x12mg |
MMC Cohort C 2x12 mg |
MMC Cohort D max 6x12mg |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Adverse events | G1 | G2 | G3 | G1 | G2 | G1 | G2 | G1 | G2 | G1 | G2 |
Clinical | |||||||||||
Fatigue | 2/16 | - | - | - | - | - | - | 3/3 | - | 2/6 | - |
Pain | 5/16 | 2/16 | - | - | - | - | - | - | - | 1/6 | - |
Nausea | 3/16 | 2/16 | - | - | - | - | - | - | - | 1/6 | - |
Emesis | 2/16 | 2/16 | - | - | - | - | - | - | - | 1/6 | - |
Gastrointestinal ulcer | - | 4/16 | 1/16 | - | - | - | - | - | - | - | - |
Biochemical | |||||||||||
Leukopenia | 2/16 | - | - | - | - | - | - | 2/3 | - | 4/6 | 2/6 |
Thrombocytopenia | 3/16 | 1/16 | - | 1/2 | - | 1/1 | - | 3/3 | - | 4/6 | 2/6 |
Anaemia | - | - | - | - | - | - | - | - | - | 4/6 | - |
Increased aspartate aminotransferase | 5/16 | 1/16 | - | - | - | - | - | - | - | 2/6 | - |
Increased alanine aminotransferase | 3/16 | 1/16 | - | - | - | - | - | - | - | 1/6 | - |
Increased bilirubin | - | - | - | - | - | - | - | 1/3 | 1/3 | - | - |
Increased alkaline phosphatase | 2/16 | 1/16 | - | - | - | - | - | 1/3 | - | 2/6 | - |
Decreased eGFR | - | 1/16 | - | - | - | - | - | - | - | - | - |
Increased gamma-glutamyl transferase | 4/16 | 1/16 | - | - | - | - | - | 1/3 | - | 4/6 | - |
eGFR = estimated glomerular filtration rate